{
  "docId": "019de074-ac90-73cc-861b-68f2ee02d519",
  "docSlug": "5e6566e4cd37b5a4c67661e229e01a81",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 41 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 41,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a progress-tracking visual to show specific drug candidates and their trial names/indications.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ac90-73cc-861b-68f2ee02d519/7",
  "deckHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519",
  "deckJsonHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519.json",
  "deckAnchorHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.15,
        "y": 0.85
      },
      "kind": "callout",
      "text": "10 potential blockbuster opportunities from 30 Phase III trials planned in 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3f64d0c-8c3c-40b0-b44e-197dca73141d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "Phase III trial initiation defined as achievement of first patient dosed; 2. AVANZAR and TROPION-Lung07 Phase III first patient dosed ahead of Q4/FY 2022 results on 09 February 2023. NSCLC = non-small cell lung cancer; 1L = first-line...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "456e27fe-33a6-485a-820d-839fbbf2c569",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.8,
        "x": 0.15,
        "y": 0.3
      },
      "kind": "list",
      "text": "Dato-DXd (AVANZAR, 1L NSCLC), Dato-DXd (TROPION-Lung07, non-squamous 1L NSCLC), Tezspire (CROSSING, EoE), AZD3152 (SUPERNOVA, COVID-19), camizestrant (CAMBRIA-1, HR+/HER2- BC), Ultomiris (ARTEMIS, CSA-AKI)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78b34e69-eb09-40fc-a8ee-2181f490b748",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "title",
      "text": "Potential to initiate 30 Phase III trials, with six dosed to-date in 2023",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b92e4613-ab74-4734-8607-7cce3c7e2dc1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Accelerating our late-stage pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3aea78cd-fe07-4619-8e1d-3a9513e7a18c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 5,
      "beatId": "b9662d01-f7bb-4746-bd60-26f7dc907205",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The slides highlighting financial results and key takeaways demonstrate the need for progress in various business areas",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}